Fig. 1: Tumor marker response to olaparib.
From: Olaparib for metastatic breast cancer in a patient with a germline PALB2 variant
Compared with pretreatment levels, there was a marked reduction in circulating CA 15–3 at 3 months after initiation of olaparib, which was deepened and sustained after 8 months of treatment.
